Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1980 Aug;29(2):489–493. doi: 10.1128/iai.29.2.489-493.1980

Polyvalent antisera to Pseudomonas ribosomal vaccines: protection of mice against clinically isolated strains.

M M Lieberman, G L Wright, K M Wolcott, D C McKissock-Desoto
PMCID: PMC551144  PMID: 6783532

Abstract

The preparation of polyvalent antisera to ribosomal vaccines from Pseudomonas aeruginosa is described. The ability of these antisera to protect mice by passive immunization against challenge with randomly chosen, clinically isolated strains of P. aeruginosa is reported. Significant protection was achieved against 34 of 40 strains tested (85%). Included among these strains against which protection was achieved were four mucoid strains. In addition, the degree of cross-protection attainable by the ribosomal vaccines was investigated. The results obtained indicated that these vaccines are generally serotype specific.

Full text

PDF
489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe C., Shionoya H., Hirao Y., Okada K., Homma J. Y. Common protective antigen (OEP) of Pseudomonas aeruginosa. Jpn J Exp Med. 1975 Oct;45(5):355–359. [PubMed] [Google Scholar]
  2. Alms T. H., Bass J. A. Immunization against Pseudomonas aeruginosa. II. Purification and characterization of the protective factor from the alcohol-precipitated fraction. J Infect Dis. 1967 Jun;117(3):257–264. doi: 10.1093/infdis/117.3.257. [DOI] [PubMed] [Google Scholar]
  3. Braude A. I., Ziegler E. J., Douglas H., McCutchan J. A. Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. J Infect Dis. 1977 Aug;136 (Suppl):S167–S173. doi: 10.1093/infdis/136.supplement.s167. [DOI] [PubMed] [Google Scholar]
  4. Daoulas-Le Bourdelles F., Berche P., Véron M. Vaccin acellulaire de Pseudomonas aeruginosa. II. -- Estimation du pouvoir protecteur d'un immunsérum par une mesure de la clairance bactérienne. Ann Microbiol (Paris) 1977 Jul;128B(1):61–71. [PubMed] [Google Scholar]
  5. Doggett R. G., Harrison G. M. Pseudomonas aeruginosa: immune status in patients with cystic fibrosis. Infect Immun. 1972 Oct;6(4):628–635. doi: 10.1128/iai.6.4.628-635.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fisher M. W. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection. J Infect Dis. 1977 Aug;136 (Suppl):S181–S185. doi: 10.1093/infdis/136.supplement.s181. [DOI] [PubMed] [Google Scholar]
  7. Fisher M. W. Development of immunotherapy for infections due to Pseudomonas aeruginosa. J Infect Dis. 1974 Nov;130 (Suppl)(0):S149–S151. doi: 10.1093/infdis/130.supplement.s149. [DOI] [PubMed] [Google Scholar]
  8. Govan J. R., Fyfe J. A. Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro. J Antimicrob Chemother. 1978 May;4(3):233–240. doi: 10.1093/jac/4.3.233. [DOI] [PubMed] [Google Scholar]
  9. Hanessian S., Regan W., Watson D., Haskell T. H. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol. 1971 Feb 17;229(7):209–210. doi: 10.1038/newbio229209a0. [DOI] [PubMed] [Google Scholar]
  10. Hoiby N., Mathiesen L. Pseudomonas aeruginosa infection in cystic fibrosis. Distribution of B and T lymphocytes in relation to the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):559–566. [PubMed] [Google Scholar]
  11. Hoiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response. Acta Pathol Microbiol Scand B Microbiol Immunol. 1974 Aug;82(4):551–558. [PubMed] [Google Scholar]
  12. Jones R. J., Roe E. A., Gupta J. L. Low mortality in burned patients in a Pseudomonas vaccine trial. Lancet. 1978 Aug 19;2(8086):401–403. doi: 10.1016/s0140-6736(78)91868-8. [DOI] [PubMed] [Google Scholar]
  13. Lieberman M. M. Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine. Infect Immun. 1977 Aug;17(2):471–473. doi: 10.1128/iai.17.2.471-473.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lieberman M. M., McKissock D. C., Wright G. L. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions. Infect Immun. 1979 Feb;23(2):509–521. doi: 10.1128/iai.23.2.509-521.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lieberman M. M. Pseudomonas ribosomal vaccines: preparation, properties, and immunogenicity. Infect Immun. 1978 Jul;21(1):76–86. doi: 10.1128/iai.21.1.76-86.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Liu P. V., Yoshii S., Hsieh H. Exotoxins of Pseudomonas aeruginosa. II. Concentration, purification, and characterization of exotoxin A. J Infect Dis. 1973 Oct;128(4):514–519. doi: 10.1093/infdis/128.4.514. [DOI] [PubMed] [Google Scholar]
  17. Miler J. M., Spilsbury J. F., Jones R. J., Roe E. A., Lowbury E. J. A new polyvalent Pseudomonas vaccine. J Med Microbiol. 1977 Feb;10(1):19–27. doi: 10.1099/00222615-10-1-19. [DOI] [PubMed] [Google Scholar]
  18. Moody M. R., Kessel R. W., Young V. M., Fiset P. Role of nonagglutinating antibody in the protracted immunity of vaccinated mice to Pseudomonas aeruginosa infection. Infect Immun. 1978 Sep;21(3):905–913. doi: 10.1128/iai.21.3.905-913.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Pavlovskis O. R., Pollack M., Callahan L. T., 3rd, Iglewski B. H. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun. 1977 Dec;18(3):596–602. doi: 10.1128/iai.18.3.596-602.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pennington J. E. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis. 1979 Jul;140(1):73–80. doi: 10.1093/infdis/140.1.73. [DOI] [PubMed] [Google Scholar]
  21. Pennington J. E., Miler J. J. Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun. 1979 Sep;25(3):1029–1034. doi: 10.1128/iai.25.3.1029-1034.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pier G. B., Sidberry H. F., Sadoff J. C. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa. Infect Immun. 1978 Dec;22(3):919–925. doi: 10.1128/iai.22.3.919-925.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pier G. B., Sidberry H. F., Zolyomi S., Sadoff J. C. Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa. Infect Immun. 1978 Dec;22(3):908–918. doi: 10.1128/iai.22.3.908-918.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sensakovic J. W., Bartell P. F. Glycolipoprotein from Pseudomonas aeruginosa as a protective antigen against P. aeruginosa infection in mice. Infect Immun. 1977 Nov;18(2):304–309. doi: 10.1128/iai.18.2.304-309.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Snell K., Holder I. A., Leppla S. A., Saelinger C. B. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa. Infect Immun. 1978 Mar;19(3):839–845. doi: 10.1128/iai.19.3.839-845.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wesley J., Fisher A., Fisher M. W. Immunization against Pseudomonas in infection after thermal injury. J Infect Dis. 1974 Nov;130 (Suppl)(0):S152–S158. doi: 10.1093/infdis/130.supplement.s152. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES